問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chung Shan Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 402Taichung CityTaichung South

Recruiting Trial

197Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

518Cases

2007-05-21 - 2007-05-21

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-05-08 - 2011-05-08

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-06-30 - 2024-09-02

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-11-29 - 2027-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-03-28 - 2026-08-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-08-26 - 2026-07-23

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2015-10-01 - 2017-07-31

Phase I/II

Completed
A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus

  • Condition/Disease

    Staphylococcus Aureus bacteremia

  • Test Drug

    514G3

Participate Sites
6Sites

Terminated4Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2024-01-15 - 2029-12-31

Phase III

Active
Beamion LUNG-2: A Phase III, open-label, randomized, active- controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Condition/Disease

    unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Test Drug

    Zongertinib

Participate Sites
5Sites

Recruiting5Sites

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and Hypertension

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
11Sites

Not yet recruiting5Sites

Recruiting6Sites

2023-05-10 - 2025-04-30

Phase II

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    SerpinPCSterile Water for Injection 10mL vial

Participate Sites
3Sites

Recruiting3Sites

1 23 24 25 26 27 52
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB